On May 1, the Australian government announced the inclusion of Zinbryta (daclizumab) on the Pharmaceutical Benefits Scheme (PBS) for the treatment of relapsing remitting MS.
Zinbryta is registered for the treatment of relapsing forms of MS to delay the progression of physical disability and to reduce the frequency of relapses. Given as a monthly injection, it releases an antibody that blocks the activity of interleukin-2, a chemical messenger of the immune system. It interferes with the activation and growth of immune cells that attack nerve cells to produce episodes of relapsing remitting MS.
MSWA welcomes the addition to the PBS. It will offer another affordable treatment option for relapsing remitting MS allowing doctors and people living with MS to find effective treatments to suit their individual circumstance. Any changes to medications should be made in consultation with your neurologist.